TC
BMRN icon

Telemus Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Telemus Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,378
Closed -$1.06M – 388
2020
Q3 		$1.06M Buy
13,378
+11,047
+474% +$1.12M 0.08% 190
2020
Q2 		$294K Buy
+2,331
New +$232K 0.02% 344

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Telemus Capital's BMRN Position: Q4 2020 in Review

Telemus Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 13,378 shares — an estimated $1.06M sold.

Telemus Capital first reported a position in BMRN in Q2 2020 and held it in 2 quarters. The position peaked at $1.06M in Q3 2020. 537 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

  • Telemus Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Telemus Capital sold 13,378 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $1.06M.
  • Telemus Capital first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Telemus Capital's BioMarin Pharmaceuticals position peaked at $1.06M in Q3 2020.
  • 537 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Telemus Capital's 13F filing for Q4 2020, filed 28 Jan 2021.